Kolexia
Gidaro Teresa Neurologie
Gidaro Teresa
Neurologie
Bioprojet Pharma
Paris, France
115 Activités
381 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Dystrophies musculaires Maladies musculaires Atrophie Myopathie de Duchenne Amyotrophie Amyotrophie spinale Myopathies congénitales structurales Maladies neuromusculaires Dystrophie musculaire oculopharyngée

Collaborateurs

Voir plus
Servais Laurent
Servais Laurent
Hôpital Armand Trousseau, Paris, France
Seferian Andreea
Seferian Andreea
Hôpital Pitie Salpetriere, Paris, France
Cuisset Jean-Marie
Cuisset Jean-Marie
Hôpital Roger Salengro, Lille, France
Gargaun Elena
Gargaun Elena
Centre Hospitalier du Mans, Le Mans, France

Industries

Voir plus
Santhera
1 collaboration(s)
Dernière en 2019
AveXis
1 collaboration(s)
Dernière en 2019
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Pathogenic DPAGT1 variants in limb-girdle congenital myasthenic syndrome (LG-CMS) associated with tubular aggregates and ORAI1 hypoglycosylation.
Neuropathology and applied neurobiology   20 décembre 2023
Clinical and genetic features of patients suffering from CMT4J.
Journal of neurology   11 novembre 2023
Relationship between markers of disease activity and progression in skeletal muscle of GNE myopathy patients using quantitative nuclear magnetic resonance imaging and P nuclear magnetic resonance spectroscopy.
Quantitative imaging in medicine and surgery   15 avril 2022
A negative feedback loop between fibroadipogenic progenitors and muscle fibres involving endothelin promotes human muscle fibrosis.
Journal of cachexia, sarcopenia and muscle   22 mars 2022
CLINICAL RESEARCH: O.7 Prospective natural history of upper limb disease evolution in Duchenne muscular dystrophy
Neuromuscular disorders : NMD   01 octobre 2021
Upper limb disease evolution in exon 53 skipping eligible patients with Duchenne muscular dystrophy.
Annals of clinical and translational neurology   28 août 2021
Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA): Expanded Access Program (EAP) to Provide Nusinersen to Patients With Infantile-onset Spinal Muscular Atrophy (SMA)
Essai Clinique (Biogen)   01 avril 2021
Natural history of Type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study.
Annals of clinical and translational neurology   24 décembre 2020
Global versus individual muscle segmentation to assess quantitative MRI-based fat fraction changes in neuromuscular diseases.
European radiology   21 novembre 2020
DMD – BIOMARKERS & OUTCOME MEASURES: P.129 Grip strength is a reliable outcome measure throughout the life span of patients with Duchenne muscular dystrophy
Neuromuscular disorders : NMD   01 octobre 2020